生物相似藥胰島素的全球市場:甘精胰島素80%以上佔的市場佔有率
市場調查報告書
商品編碼
1123700

生物相似藥胰島素的全球市場:甘精胰島素80%以上佔的市場佔有率

Market Study on Biosimilar Insulin: More Than 80% Market Share Accounted for by Insulin Glargine

出版日期: | 出版商: Persistence Market Research | 英文 250 Pages | 商品交期: 2-5個工作天內

價格

本報告提供全球生物相似藥胰島素市場調查,市場概要和趨勢,成功因素,市場背景,COVID-19影響,各市場區隔、各地區的市場分析與預測,競爭情形等彙整資料。

目錄

第1章 摘要整理

第2章 市場概要

  • 市場範圍/分類
  • 市場定義/範圍/規定
  • 蘊藏和除外

第3章 主要市場趨勢

  • 影響市場的主要趨勢
  • 產品創新、開發趨勢

第4章 主要成功因素

  • 主要的產品的賣點/功能分析
  • 法規設想情境
  • 主要的推銷策略:各製造廠商
  • 近幾年的產品銷售
  • 價值鏈分析
  • 產品採用分析:各地區

第5章 市場背景

  • 宏觀經濟要素
    • 全球GDP的成長預測
    • 全球醫療產業預測
    • 親市場分析(胰島素市場)
  • 預測要素 - 相關性及影響
    • 糖尿病患者增加
    • 研究開發活動增加
    • 新產品的銷售
    • 臨床試驗數增加
    • 胰島素的專利到期
    • 老年人口增加
    • 胰島素製造商增加
    • 對成本效益高的產品的要求
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會分析

第6章 COVID-19危機的分析

  • 市場設想情境(2021年)
  • COVID-19及影響分析
    • 各產品
    • 各流通管道
    • 各地區

第7章 全球生物相似藥胰島素市場需求(價值、規模)的分析與預測

  • 市場成果分析
  • 現在及未來市場預測
    • 與前一年同期比較成長趨勢分析

第8章 全球生物相似藥胰島素市場 - 價格分析

  • 地區價格分析:各產品
  • 世界平均價格分析基準
  • 價格明細
    • 廠商價格
    • 批發價格
  • 價格設定的前提

第9章 全球生物相似藥胰島素市場分析與預測:各產品

  • 簡介/主要調查結果
  • 市場成果分析:各產品
  • 現在及未來市場分析與預測:各產品
    • 甘精胰島素
    • 胰島素類似物
    • 其他
  • 市場魅力分析:各產品

第10章 全球生物相似藥胰島素市場分析與預測:各流通管道

  • 簡介/主要調查結果
  • 市場成果分析:各流通管道
  • 現在及未來市場分析與預測: 各流通管道
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場魅力分析:各流通管道

第11章 全球生物相似藥胰島素市場分析與預測:各地區

  • 簡介
  • 市場成果分析:各地區
  • 現在及未來市場分析與預測:各地區
    • 北美
    • 南美
    • 歐洲
    • 亞太地區
    • 中東、非洲
  • 市場魅力分析:各地區

第12章 北美的生物相似藥胰島素市場分析與預測

  • 簡介
  • 價格分析
  • 市場趨勢分析(成果):市場各分類
  • 現在及未來市場分析與預測:市場各分類
    • 各國
    • 各產品
    • 各流通管道
  • 市場魅力分析
    • 各國
    • 各產品
    • 各流通管道
  • 主要市場參與者 - 強度製圖
  • 促進因素、阻礙因素 - 影響分析
  • 各國分析與預測
    • 美國的生物相似藥胰島素市場
    • 加拿大的生物相似藥胰島素市場

第13章 南美的生物相似藥胰島素市場分析與預測

  • 簡介
  • 價格分析
  • 市場趨勢分析(成果):市場各分類
  • 現在及未來市場分析與預測:市場各分類
    • 各國
    • 各產品
    • 各流通管道
  • 市場魅力分析
    • 各國
    • 各產品
    • 各流通管道
  • 主要市場參與者 - 強度製圖
  • 促進因素、阻礙因素 - 影響分析
  • 各國分析與預測
    • 巴西的生物相似藥胰島素市場
    • 阿根廷的生物相似藥胰島素市場
    • 墨西哥的生物相似藥胰島素市場

第14章 歐洲的生物相似藥胰島素市場分析與預測

  • 簡介
  • 價格分析
  • 市場趨勢分析(成果):市場各分類
  • 現在及未來市場分析與預測:市場各分類
    • 各國
    • 各產品
    • 各流通管道
  • 市場魅力分析
    • 各國
    • 各產品
    • 各流通管道
  • 主要市場參與者 - 強度製圖
  • 促進因素、阻礙因素 - 影響分析
  • 各國分析與預測
    • 德國的生物相似藥胰島素市場
    • 法國的生物相似藥胰島素市場
    • 義大利的生物相似藥胰島素市場
    • 西班牙的生物相似藥胰島素市場
    • 英國的生物相似藥胰島素市場
    • 荷比盧三國加盟國的生物相似藥胰島素市場
    • 北歐各國的生物相似藥胰島素市場
    • 俄羅斯的生物相似藥胰島素市場

第15章 亞太地區的生物相似藥胰島素市場分析與預測

  • 簡介
  • 價格分析
  • 市場趨勢分析(成果):市場各分類
  • 現在及未來市場分析與預測:市場各分類
    • 各國
    • 各產品
    • 各流通管道
  • 市場魅力分析
    • 各國
    • 各產品
    • 各流通管道
  • 主要市場參與者 - 強度製圖
  • 促進因素、阻礙因素 - 影響分析
  • 各國分析與預測
    • 中國的生物相似藥胰島素市場
    • 日本的生物相似藥胰島素市場
    • 印度的生物相似藥胰島素市場
    • 澳洲的生物相似藥胰島素市場
    • 紐西蘭的生物相似藥胰島素市場

第16章 中東、非洲的生物相似藥胰島素市場分析與預測

  • 簡介
  • 價格分析
  • 市場趨勢分析(成果):市場各分類
  • 現在及未來市場分析與預測:市場各分類
    • 各國
    • 各產品
    • 各流通管道
  • 市場魅力分析
    • 各國
    • 各產品
    • 各流通管道
  • 主要市場參與者 - 強度製圖
  • 促進因素、阻礙因素 - 影響分析
  • 各國分析與預測
    • 波灣合作理事會(GCC)各國的生物相似藥胰島素市場
    • 以色列的生物相似藥胰島素市場
    • 土耳其的生物相似藥胰島素市場
    • 埃及生物相似藥胰島素市場
    • 北非的生物相似藥胰島素市場
    • 南非的生物相似藥胰島素市場

第17章 市場結構分析

  • 市場分析:各企業等級
  • 主要企業的市場佔有率分析
  • 市場影響分析
    • 企業的地區據點
    • 作業平台類型的足跡: 各企業
    • 流通管道的足跡: 各企業

第18章 競爭分析

  • 競爭儀表板
  • 競爭的基準
  • 競爭詳細內容
    • Biocon
    • Eli Lilly and Company
    • Sanofi
    • BGP Pharma
    • Aspen
    • Mylan(Viatris)

第19章 前提與使用的縮寫

第20章 調查手法

Product Code: PMRREP11674

Scope of the Report:

The latest publication by Persistence Market Research on the global biosimilar insulin market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for biosimilar insulin market products and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the biosimilar insulin market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the biosimilar insulin market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the biosimilar insulin market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments:

Persistence Market Research's study on the biosimilar insulin market offers information divided into three important segments - product, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Product

  • Insulin Glargine
  • Insulin Analog
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

Key Questions Answered:

  • Which regions will continue to remain the most profitable markets for biosimilar insulin over the coming years?
  • How will changing trends impact the market?
  • How has the COVID-19 crisis impacted market growth?
  • How can market players capture the low-hanging opportunities in developed regions?
  • What are the strategies of stakeholders in the market to shape their position in this landscape?
  • What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
  • What are the developmental trends that will impact the market?
  • How can companies in the biosimilar insulin market avail themselves the growth opportunities in developed and emerging sectors?

Research Methodology

In Persistence Market Research's study, a unique research methodology is utilized to conduct extensive research on the growth of the biosimilar insulin market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research's projections on the growth prospects of the biosimilar insulin market more accurate and reliable.

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusion And Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Key Products USP/Feature Analysis
  • 4.2. Regulatory Scenario
  • 4.3. Key Promotional Strategies By Manufacturers
  • 4.4. Recent Product Launches
  • 4.5. Value Chain Analysis
  • 4.6. Product Adoption Analysis by Region

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Industry Outlook
    • 5.1.3. Parent Market Analysis (Insulin Market)
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Growing Prevalence Of Diabetes
    • 5.2.2. Increasing Research and Development Activities
    • 5.2.3. New Product Launches
    • 5.2.4. Increasing Number Of Clinical Trials
    • 5.2.5. Patent Expiry for Insulin
    • 5.2.6. Growing Geriatric Population
    • 5.2.7. Increasing Insulin Manufacturers
    • 5.2.8. Requirement of Cost-Efficient Products
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. 2021 Market Scenario
  • 6.2. COVID-19 and Impact Analysis
    • 6.2.1. By Product
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Region

7. Global Biosimilar Insulin Market Demand (in Value or Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2017-2021
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Biosimilar Insulin Market - Pricing Analysis

  • 8.1. Regional Pricing Analysis By Product
  • 8.2. Global Average Pricing Analysis Benchmark
  • 8.3. Pricing Break-up
    • 8.3.1. Manufacturer Level Pricing
    • 8.3.2. Distributor Level Pricing
  • 8.4. Pricing Assumptions

9. Global Biosimilar Insulin Market Analysis 2017-2021 and Forecast 2022-2032, By Product

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Product, 2017-2021
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2032
    • 9.3.1. Insulin Glargine
    • 9.3.2. Insulin Analog
    • 9.3.3. Others
  • 9.4. Market Attractiveness Analysis By Product

10. Global Biosimilar Insulin Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2017-2021
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Biosimilar Insulin Market Analysis 2017-2021 and Forecast 2022-2032, By Region

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2017-2021
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2032
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. Europe
    • 11.3.4. Asia Pacific (APAC)
    • 11.3.5. Middle East and Africa (MEA)
  • 11.4. Market Attractiveness Analysis By Region

12. North America Biosimilar Insulin Market Analysis 2017-2021 and Forecast 2022-2032

  • 12.1. Introduction
  • 12.2. Pricing Analysis
  • 12.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
  • 12.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
    • 12.4.1. By Country
      • 12.4.1.1. U.S.
      • 12.4.1.2. Canada
    • 12.4.2. By Product
    • 12.4.3. By Distribution Channel
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Country
    • 12.5.2. By Product
    • 12.5.3. By Distribution Channel
  • 12.6. Key Market Participants - Intensity Mapping
  • 12.7. Drivers and Restraints - Impact Analysis
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. U.S. Biosimilar Insulin Market
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.1.2.1. By Product
        • 12.8.1.2.2. By Distribution Channel
    • 12.8.2. Canada Biosimilar Insulin Market
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.2.2.1. By Product
        • 12.8.2.2.2. By Distribution Channel

13. Latin America Biosimilar Insulin Market Analysis 2017-2021 and Forecast 2022-2032

  • 13.1. Introduction
  • 13.2. Pricing Analysis
  • 13.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
  • 13.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
    • 13.4.1. By Country
      • 13.4.1.1. Brazil
      • 13.4.1.2. Argentina
      • 13.4.1.3. Mexico
      • 13.4.1.4. Rest of Latin America
    • 13.4.2. By Product
    • 13.4.3. By Distribution Channel
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Country
    • 13.5.2. By Product
    • 13.5.3. By Distribution Channel
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Brazil Biosimilar Insulin Market
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Product
        • 13.8.1.2.2. By Distribution Channel
    • 13.8.2. Argentina Biosimilar Insulin Market
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Product
        • 13.8.2.2.2. By Distribution Channel
    • 13.8.3. Mexico Biosimilar Insulin Market
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.3.2.1. By Product
        • 13.8.3.2.2. By Distribution Channel

14. Europe Biosimilar Insulin Market Analysis 2017-2021 and Forecast 2022-2032

  • 14.1. Introduction
  • 14.2. Pricing Analysis
  • 14.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
  • 14.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
    • 14.4.1. By Country
      • 14.4.1.1. Germany
      • 14.4.1.2. Italy
      • 14.4.1.3. France
      • 14.4.1.4. U.K.
      • 14.4.1.5. Spain
      • 14.4.1.6. BENELUX
      • 14.4.1.7. Nordic Countries
      • 14.4.1.8. Russia
      • 14.4.1.9. Rest of Europe
    • 14.4.2. By Product
    • 14.4.3. By Distribution Channel
  • 14.5. Market Attractiveness Analysis
    • 14.5.1. By Country
    • 14.5.2. By Product
    • 14.5.3. By Distribution Channel
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Germany Biosimilar Insulin Market
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Product
        • 14.8.1.2.2. By Distribution Channel
    • 14.8.2. France Biosimilar Insulin Market
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Product
        • 14.8.2.2.2. By Distribution Channel
    • 14.8.3. Italy Biosimilar Insulin Market
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Product
        • 14.8.3.2.2. By Distribution Channel
    • 14.8.4. Spain Biosimilar Insulin Market
      • 14.8.4.1. Introduction
      • 14.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.4.2.1. By Product
        • 14.8.4.2.2. By Distribution Channel
    • 14.8.5. U.K. Biosimilar Insulin Market
      • 14.8.5.1. Introduction
      • 14.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.5.2.1. By Product
        • 14.8.5.2.2. By Distribution Channel
    • 14.8.6. BENULUX Biosimilar Insulin Market
      • 14.8.6.1. Introduction
      • 14.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.6.2.1. By Product
        • 14.8.6.2.2. By Distribution Channel
    • 14.8.7. Nordic Countries Biosimilar Insulin Market
      • 14.8.7.1. Introduction
      • 14.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.7.2.1. By Product
        • 14.8.7.2.2. By Distribution Channel
    • 14.8.8. Russia Biosimilar Insulin Market
      • 14.8.8.1. Introduction
      • 14.8.8.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.8.2.1. By Product
        • 14.8.8.2.2. By Distribution Channel

15. Asia Pacific (APAC) Biosimilar Insulin Market Analysis 2017-2021 and Forecast 2022-2032

  • 15.1. Introduction
  • 15.2. Pricing Analysis
  • 15.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
  • 15.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
    • 15.4.1. By Country
      • 15.4.1.1. China
      • 15.4.1.2. Japan
      • 15.4.1.3. India
      • 15.4.1.4. Australia
      • 15.4.1.5. New Zealand
    • 15.4.2. By Product
    • 15.4.3. By Distribution Channel
  • 15.5. Market Attractiveness Analysis
    • 15.5.1. By Country
    • 15.5.2. By Product
    • 15.5.3. By Distribution Channel
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. China Biosimilar Insulin Market
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Product
        • 15.8.1.2.2. By Distribution Channel
    • 15.8.2. Japan Biosimilar Insulin Market
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Product
        • 15.8.2.2.2. By Distribution Channel
    • 15.8.3. India Biosimilar Insulin Market
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Product
        • 15.8.3.2.2. By Distribution Channel
    • 15.8.4. Australia Biosimilar Insulin Market
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Product
        • 15.8.4.2.2. By Distribution Channel
    • 15.8.5. New Zealand Biosimilar Insulin Market
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Product
        • 15.8.5.2.2. By Distribution Channel

16. Middle East and Africa (MEA) Biosimilar Insulin Market Analysis 2017-2021 and Forecast 2022-2032

  • 16.1. Introduction
  • 16.2. Pricing Analysis
  • 16.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
  • 16.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
    • 16.4.1. By Country
      • 16.4.1.1. GCC Countries
      • 16.4.1.2. Israel
      • 16.4.1.3. Turkey
      • 16.4.1.4. Egypt
      • 16.4.1.5. North Africa
      • 16.4.1.6. South Africa
      • 16.4.1.7. Rest of Middle East and Africa
    • 16.4.2. By Product
    • 16.4.3. By Distribution Channel
  • 16.5. Market Attractiveness Analysis
    • 16.5.1. By Country
    • 16.5.2. By Product
    • 16.5.3. By Distribution Channel
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. GCC Countries Biosimilar Insulin Market
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Product
        • 16.8.1.2.2. By Distribution Channel
    • 16.8.2. Israel Biosimilar Insulin Market
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Product
        • 16.8.2.2.2. By Distribution Channel
    • 16.8.3. Turkey Biosimilar Insulin Market
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Product
        • 16.8.3.2.2. By Distribution Channel
    • 16.8.4. Egypt Biosimilar Insulin Market
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Product
        • 16.8.4.2.2. By Distribution Channel
    • 16.8.5. North Africa Biosimilar Insulin Market
      • 16.8.5.1. Introduction
      • 16.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.5.2.1. By Product
        • 16.8.5.2.2. By Distribution Channel
    • 16.8.6. South Africa Biosimilar Insulin Market
      • 16.8.6.1. Introduction
      • 16.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.6.2.1. By Product
        • 16.8.6.2.2. By Distribution Channel

17. Market Structure Analysis

  • 17.1. Market Analysis by Tier of Companies
  • 17.2. Market Share Analysis of Top Players
  • 17.3. Market Presence Analysis
    • 17.3.1. Regional footprint of Players
    • 17.3.2. Platform Type foot print by Players
    • 17.3.3. Channel Foot Print by Players

18. Competition Analysis

  • 18.1. Competition Dashboard
  • 18.2. Competition Benchmarking
  • 18.3. Competition Deep Dive
    • 18.3.1. Biocon
      • 18.3.1.1. Overview
      • 18.3.1.2. Product Portfolio
      • 18.3.1.3. Key Financials
      • 18.3.1.4. Geographical Footprint
      • 18.3.1.5. SWOT Analysis
      • 18.3.1.6. Key Developments
      • 18.3.1.7. Strategy Overview
        • 18.3.1.7.1. Channel Strategy
        • 18.3.1.7.2. Marketing Strategy
        • 18.3.1.7.3. Product Strategy
    • 18.3.2. Eli Lilly and Company
      • 18.3.2.1. Overview
      • 18.3.2.2. Product Portfolio
      • 18.3.2.3. Key Financials
      • 18.3.2.4. Geographical Footprint
      • 18.3.2.5. SWOT Analysis
      • 18.3.2.6. Key Developments
      • 18.3.2.7. Strategy Overview
        • 18.3.2.7.1. Channel Strategy
        • 18.3.2.7.2. Marketing Strategy
        • 18.3.2.7.3. Product Strategy
    • 18.3.3. Sanofi
      • 18.3.3.1. Overview
      • 18.3.3.2. Product Portfolio
      • 18.3.3.3. Key Financials
      • 18.3.3.4. Geographical Footprint
      • 18.3.3.5. SWOT Analysis
      • 18.3.3.6. Key Developments
      • 18.3.3.7. Strategy Overview
        • 18.3.3.7.1. Channel Strategy
        • 18.3.3.7.2. Marketing Strategy
        • 18.3.3.7.3. Product Strategy
    • 18.3.4. BGP Pharma
      • 18.3.4.1. Overview
      • 18.3.4.2. Product Portfolio
      • 18.3.4.3. Key Financials
      • 18.3.4.4. Geographical Footprint
      • 18.3.4.5. SWOT Analysis
      • 18.3.4.6. Key Developments
      • 18.3.4.7. Strategy Overview
        • 18.3.4.7.1. Channel Strategy
        • 18.3.4.7.2. Marketing Strategy
        • 18.3.4.7.3. Product Strategy
    • 18.3.5. Aspen
      • 18.3.5.1. Overview
      • 18.3.5.2. Product Portfolio
      • 18.3.5.3. Key Financials
      • 18.3.5.4. Geographical Footprint
      • 18.3.5.5. SWOT Analysis
      • 18.3.5.6. Key Developments
      • 18.3.5.7. Strategy Overview
        • 18.3.5.7.1. Channel Strategy
        • 18.3.5.7.2. Marketing Strategy
        • 18.3.5.7.3. Product Strategy
    • 18.3.6. Mylan (Viatris)
      • 18.3.6.1. Overview
      • 18.3.6.2. Product Portfolio
      • 18.3.6.3. Key Financials
      • 18.3.6.4. Geographical Footprint
      • 18.3.6.5. SWOT Analysis
      • 18.3.6.6. Key Developments
      • 18.3.6.7. Strategy Overview
        • 18.3.6.7.1. Channel Strategy
        • 18.3.6.7.2. Marketing Strategy
        • 18.3.6.7.3. Product Strategy

19. Assumptions and Acronyms Used

20. Research Methodology

List of Tables

  • Table 1: Global Biosimilar Insulin Market Value (US$ Mn) Forecast by Region, 2017 & 2032
  • Table 2: Global Biosimilar Insulin Market Value (US$ Mn) Forecast by Product, 2017 & 2032
  • Table 3: Global Biosimilar Insulin Market Value (US$ Mn) Forecast By Distribution Channel, 2017 & 2032
  • Table 4: North America Biosimilar Insulin Market Value (US$ Mn) Forecast by Country, 2017 & 2032
  • Table 5: North America Biosimilar Insulin Market Value (US$ Mn) Forecast by Product, 2017 & 2032
  • Table 6: North America Biosimilar Insulin Market Value (US$ Mn) Forecast By Distribution Channel, 2017 & 2032
  • Table 7: Latin America Biosimilar Insulin Market Value (US$ Mn) Forecast by Country, 2017 & 2032
  • Table 8: Latin America Biosimilar Insulin Market Value (US$ Mn) Forecast by Product, 2017 & 2032
  • Table 9: Latin America Biosimilar Insulin Market Value (US$ Mn) Forecast By Distribution Channel, 2017 & 2032
  • Table 10: Europe Biosimilar Insulin Market Value (US$ Mn) Forecast by Country, 2017 & 2032
  • Table 11: Europe Biosimilar Insulin Market Value (US$ Mn) Forecast by Product, 2017 & 2032
  • Table 12: Europe Biosimilar Insulin Market Value (US$ Mn) Forecast By Distribution Channel, 2017 & 2032
  • Table 13: Asia Pacific (APAC) Biosimilar Insulin Market Value (US$ Mn) Forecast by Country, 2017 & 2032
  • Table 14: Asia Pacific (APAC) Biosimilar Insulin Market Value (US$ Mn) Forecast by Product, 2017 & 2032
  • Table 15: Asia Pacific (APAC) Biosimilar Insulin Market Value (US$ Mn) Forecast By Distribution Channel, 2017 & 2032
  • Table 16: Middle East and Africa (MEA) Biosimilar Insulin Market Value (US$ Mn) Forecast by Country, 2017 & 2032
  • Table 17: Middle East and Africa (MEA) Biosimilar Insulin Market Value (US$ Mn) Forecast by Product, 2017 & 2032
  • Table 18: Middle East and Africa (MEA) Biosimilar Insulin Market Value (US$ Mn) Forecast By Distribution Channel, 2017 & 2032

List of Figures

  • Figure 1: Global Biosimilar Insulin Market Value (US$ Mn) by Product, 2022 & 2032
  • Figure 2: Global Biosimilar Insulin Market Value (US$ Mn) By Distribution Channel, 2022 & 2032
  • Figure 3: Global Biosimilar Insulin Market Value (US$ Mn) by Region, 2022 & 2032
  • Figure 4: Global Biosimilar Insulin Market Value (US$ Mn) Analysis by Region, 2017 & 2032
  • Figure 5: Global Biosimilar Insulin Market Value Share (%) Analysis by Region, 2022 & 2032
  • Figure 6: Global Biosimilar Insulin Market Y-o-Y Growth (%) Projections by Region, 2022-2032
  • Figure 7: Global Biosimilar Insulin Market Value (US$ Mn) Analysis by Product, 2017 & 2032
  • Figure 8: Global Biosimilar Insulin Market Value Share (%) Analysis by Product, 2022 & 2032
  • Figure 9: Global Biosimilar Insulin Market Y-o-Y Growth (%) Projections by Product, 2022-2032
  • Figure 10: Global Biosimilar Insulin Market Value (US$ Mn) Analysis By Distribution Channel, 2017 & 2032
  • Figure 11: Global Biosimilar Insulin Market Value Share (%) Analysis By Distribution Channel, 2022 & 2032
  • Figure 12: Global Biosimilar Insulin Market Y-o-Y Growth (%) Projections By Distribution Channel, 2022-2032
  • Figure 13: Global Biosimilar Insulin Market Attractiveness by Product, 2022-2032
  • Figure 14: Global Biosimilar Insulin Market Attractiveness By Distribution Channel, 2022-2032
  • Figure 15: Global Biosimilar Insulin Market Attractiveness by Region, 2022-2032
  • Figure 16: North America Biosimilar Insulin Market Value (US$ Mn) by Product, 2022 & 2032
  • Figure 17: North America Biosimilar Insulin Market Value (US$ Mn) By Distribution Channel, 2022 & 2032
  • Figure 18: North America Biosimilar Insulin Market Value (US$ Mn) by Country, 2022 & 2032
  • Figure 19: North America Biosimilar Insulin Market Value (US$ Mn) Analysis by Country, 2017 & 2032
  • Figure 20: North America Biosimilar Insulin Market Value Share (%) Analysis by Country, 2022 & 2032
  • Figure 21: North America Biosimilar Insulin Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 22: North America Biosimilar Insulin Market Value (US$ Mn) Analysis by Product, 2017 & 2032
  • Figure 23: North America Biosimilar Insulin Market Value Share (%) Analysis by Product, 2022 & 2032
  • Figure 24: North America Biosimilar Insulin Market Y-o-Y Growth (%) Projections by Product, 2022-2032
  • Figure 25: North America Biosimilar Insulin Market Value (US$ Mn) Analysis By Distribution Channel, 2017 & 2032
  • Figure 26: North America Biosimilar Insulin Market Value Share (%) Analysis By Distribution Channel, 2022 & 2032
  • Figure 27: North America Biosimilar Insulin Market Y-o-Y Growth (%) Projections By Distribution Channel, 2022-2032
  • Figure 28: North America Biosimilar Insulin Market Attractiveness by Product, 2022-2032
  • Figure 29: North America Biosimilar Insulin Market Attractiveness By Distribution Channel, 2022-2032
  • Figure 30: North America Biosimilar Insulin Market Attractiveness by Country, 2022-2032
  • Figure 31: Latin America Biosimilar Insulin Market Value (US$ Mn) by Product, 2022 & 2032
  • Figure 32: Latin America Biosimilar Insulin Market Value (US$ Mn) By Distribution Channel, 2022 & 2032
  • Figure 33: Latin America Biosimilar Insulin Market Value (US$ Mn) by Country, 2022 & 2032
  • Figure 34: Latin America Biosimilar Insulin Market Value (US$ Mn) Analysis by Country, 2017 & 2032
  • Figure 35: Latin America Biosimilar Insulin Market Value Share (%) Analysis by Country, 2022 & 2032
  • Figure 36: Latin America Biosimilar Insulin Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 37: Latin America Biosimilar Insulin Market Value (US$ Mn) Analysis by Product, 2017 & 2032
  • Figure 38: Latin America Biosimilar Insulin Market Value Share (%) Analysis by Product, 2022 & 2032
  • Figure 39: Latin America Biosimilar Insulin Market Y-o-Y Growth (%) Projections by Product, 2022-2032
  • Figure 40: Latin America Biosimilar Insulin Market Value (US$ Mn) Analysis By Distribution Channel, 2017 & 2032
  • Figure 41: Latin America Biosimilar Insulin Market Value Share (%) Analysis By Distribution Channel, 2022 & 2032
  • Figure 42: Latin America Biosimilar Insulin Market Y-o-Y Growth (%) Projections By Distribution Channel, 2022-2032
  • Figure 43: Latin America Biosimilar Insulin Market Attractiveness by Product, 2022-2032
  • Figure 44: Latin America Biosimilar Insulin Market Attractiveness By Distribution Channel, 2022-2032
  • Figure 45: Latin America Biosimilar Insulin Market Attractiveness by Country, 2022-2032
  • Figure 46: Europe Biosimilar Insulin Market Value (US$ Mn) by Product, 2022 & 2032
  • Figure 47: Europe Biosimilar Insulin Market Value (US$ Mn) By Distribution Channel, 2022 & 2032
  • Figure 48: Europe Biosimilar Insulin Market Value (US$ Mn) by Country, 2022 & 2032
  • Figure 49: Europe Biosimilar Insulin Market Value (US$ Mn) Analysis by Country, 2017 & 2032
  • Figure 50: Europe Biosimilar Insulin Market Value Share (%) Analysis by Country, 2022 & 2032
  • Figure 51: Europe Biosimilar Insulin Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 52: Europe Biosimilar Insulin Market Value (US$ Mn) Analysis by Product, 2017 & 2032
  • Figure 53: Europe Biosimilar Insulin Market Value Share (%) Analysis by Product, 2022 & 2032
  • Figure 54: Europe Biosimilar Insulin Market Y-o-Y Growth (%) Projections by Product, 2022-2032
  • Figure 55: Europe Biosimilar Insulin Market Value (US$ Mn) Analysis By Distribution Channel, 2017 & 2032
  • Figure 56: Europe Biosimilar Insulin Market Value Share (%) Analysis By Distribution Channel, 2022 & 2032
  • Figure 57: Europe Biosimilar Insulin Market Y-o-Y Growth (%) Projections By Distribution Channel, 2022-2032
  • Figure 58: Europe Biosimilar Insulin Market Attractiveness by Product, 2022-2032
  • Figure 59: Europe Biosimilar Insulin Market Attractiveness By Distribution Channel, 2022-2032
  • Figure 60: Europe Biosimilar Insulin Market Attractiveness by Country, 2022-2032
  • Figure 61: Asia Pacific (APAC) Biosimilar Insulin Market Value (US$ Mn) by Product, 2022 & 2032
  • Figure 62: Asia Pacific (APAC) Biosimilar Insulin Market Value (US$ Mn) By Distribution Channel, 2022 & 2032
  • Figure 63: Asia Pacific (APAC) Biosimilar Insulin Market Value (US$ Mn) by Country, 2022 & 2032
  • Figure 64: Asia Pacific (APAC) Biosimilar Insulin Market Value (US$ Mn) Analysis by Country, 2017 & 2032
  • Figure 65: Asia Pacific (APAC) Biosimilar Insulin Market Value Share (%) Analysis by Country, 2022 & 2032
  • Figure 66: Asia Pacific (APAC) Biosimilar Insulin Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 67: Asia Pacific (APAC) Biosimilar Insulin Market Value (US$ Mn) Analysis by Product, 2017 & 2032
  • Figure 68: Asia Pacific (APAC) Biosimilar Insulin Market Value Share (%) Analysis by Product, 2022 & 2032
  • Figure 69: Asia Pacific (APAC) Biosimilar Insulin Market Y-o-Y Growth (%) Projections by Product, 2022-2032
  • Figure 70: Asia Pacific (APAC) Biosimilar Insulin Market Value (US$ Mn) Analysis By Distribution Channel, 2017 & 2032
  • Figure 71: Asia Pacific (APAC) Biosimilar Insulin Market Value Share (%) Analysis By Distribution Channel, 2022 & 2032
  • Figure 72: Asia Pacific (APAC) Biosimilar Insulin Market Y-o-Y Growth (%) Projections By Distribution Channel, 2022-2032
  • Figure 73: Asia Pacific (APAC) Biosimilar Insulin Market Attractiveness by Product, 2022-2032
  • Figure 74: Asia Pacific (APAC) Biosimilar Insulin Market Attractiveness By Distribution Channel, 2022-2032
  • Figure 75: Asia Pacific (APAC) Biosimilar Insulin Market Attractiveness by Country, 2022-2032
  • Figure 76: Middle East and Africa Biosimilar Insulin Market Value (US$ Mn) by Product, 2022 & 2032
  • Figure 77: Middle East and Africa Biosimilar Insulin Market Value (US$ Mn) By Distribution Channel, 2022 & 2032
  • Figure 78: Middle East and Africa Biosimilar Insulin Market Value (US$ Mn) by Country, 2022 & 2032
  • Figure 79: Middle East and Africa Biosimilar Insulin Market Value (US$ Mn) Analysis by Country, 2017 & 2032
  • Figure 80: Middle East and Africa Biosimilar Insulin Market Value Share (%) Analysis by Country, 2022 & 2032
  • Figure 81: Middle East and Africa Biosimilar Insulin Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 82: Middle East and Africa Biosimilar Insulin Market Value (US$ Mn) Analysis by Product, 2017 & 2032
  • Figure 83: Middle East and Africa Biosimilar Insulin Market Value Share (%) Analysis by Product, 2022 & 2032
  • Figure 84: Middle East and Africa Biosimilar Insulin Market Y-o-Y Growth (%) Projections by Product, 2022-2032
  • Figure 85: Middle East and Africa Biosimilar Insulin Market Value (US$ Mn) Analysis By Distribution Channel, 2017 & 2032
  • Figure 86: Middle East and Africa Biosimilar Insulin Market Value Share (%) Analysis By Distribution Channel, 2022 & 2032
  • Figure 87: Middle East and Africa Biosimilar Insulin Market Y-o-Y Growth (%) Projections By Distribution Channel, 2022-2032
  • Figure 88: Middle East and Africa Biosimilar Insulin Market Attractiveness by Product, 2022-2032
  • Figure 89: Middle East and Africa Biosimilar Insulin Market Attractiveness By Distribution Channel, 2022-2032
  • Figure 90: Middle East and Africa Biosimilar Insulin Market Attractiveness by Country, 2022-2032